Virax Biolabs
VRAX
4 hedge funds and large institutions have $71.5K invested in Virax Biolabs in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 5 closing their positions.
0% more ownership
Funds ownership: 0.06% → 0.06% (+0%)
33% less funds holding
Funds holding: 6 → 4 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
49% less capital invested
Capital invested by funds: $141K → $71.5K (-$69.8K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$24K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$23.9K |
| 3 |
HF
HRT Financial
New York
|
+$23.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$27.3K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$26.7K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$23K |
| 4 |
RS
R Squared
Central,
Hong Kong
|
-$6.08K |
| 5 |
Morgan Stanley
New York
|
-$225 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $25.6K | -$27.3K | -620 | -41% |
|
|
TSS
2
Two Sigma Securities
New York
| $15.5K | +$24K | +545 | New |
|
|
3
Citadel Advisors
Miami,
Florida
| $15.4K | +$23.9K | +542 | New |
|
|
HF
4
HRT Financial
New York
| $15K | +$23.8K | +540 | New |
|
|
XT
5
XTX Topco
George Town,
Cayman Islands
| – | -$26.7K | -475 | Closed |
|
|
6
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$23K | -416 | Closed |
|
|
RS
7
R Squared
Central,
Hong Kong
| – | -$6.08K | -108 | Closed |
|
|
8
Morgan Stanley
New York
| – | -$225 | -4 | Closed |
|
9
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$45 | -1 | Closed |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| – | -$20 | – | – |
|
VRAX Hedge Fund Activity: Q1 2025 in Review
4 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q1 2025, worth a combined $71.5K — down 49% from $141K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of VRAX and 3 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $24K. The largest seller was UBS Group, cutting an estimated $27.3K.
- 4 institutional investors held Virax Biolabs (VRAX) as of Q1 2025, down from 6 in Q4 2024.
- Funds reported $71.5K of Virax Biolabs stock for Q1 2025, down 49% quarter-over-quarter.
- 3 funds opened new Virax Biolabs positions in Q1 2025 and 5 closed out, a net change of -2 holders.
- The largest Virax Biolabs buyer in Q1 2025 was Two Sigma Securities, an estimated $24K added.
- The largest Virax Biolabs seller in Q1 2025 was UBS Group, an estimated $27.3K sold.
Based on aggregated 13F filings for Q1 2025.